Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

Article  PubMed  Google Scholar 

Al-Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SOA. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv. 2020;4:229–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–17.

Article  PubMed  Google Scholar 

Higuchi M, O’Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63–74.

Article  CAS  PubMed  Google Scholar 

Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115:2159–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med. 2006;12:945–9.

Article  CAS  PubMed  Google Scholar 

Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell. 2007;12:457–66.

Article  CAS  PubMed  Google Scholar 

Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129:465–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8:399–411.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao XN, Yan F, Lin J, Gao L, Lu XL, Wei SC, et al. AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation. Leukemia. 2015;29:1730–40.

Article  CAS  PubMed  Google Scholar 

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 2017;552:126–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23:1369–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell. 2018;22:191–205.

Article  CAS  PubMed  Google Scholar 

Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-Methyladenosine RNA demethylase. Cancer Cell. 2017;31:127–41.

Article  PubMed  Google Scholar 

Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, et al. Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell. 2019;25:137–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161:1388–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML. Oncogene. 2021;40:3786–98.

Article  PubMed  Google Scholar 

Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617–28.

Article  CAS  PubMed  Google Scholar 

de Jonge HJ, Valk PJ, Veeger NJ, ter Elst A, den Boer ML, Cloos J, et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood. 2010;116:1747–54.

Article  PubMed  Google Scholar 

Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16:903–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan Y, Hilliard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem. 2003;278:15911–6.

Article  CAS  PubMed  Google Scholar 

Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005;65:9047–55.

Article  CAS  PubMed  Google Scholar 

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019;10:278.

Article  PubMed  PubMed Central  Google Scholar 

Shao YL, Chen Z, Wang LL, Liu DH, Gao XN. The relationship between HIF1α and WTAP expression level in t(8;21) acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29:1424–8.

PubMed  Google Scholar 

Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem. 2008;283:36542–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pollard PJ, Loenarz C, Mole DR, McDonough MA, Gleadle JM, Schofield CJ, et al. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J. 2008;416:387–94.

Article  CAS  PubMed  Google Scholar 

Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS, et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA. 2009;106:4260–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramachandran S, Ient J, Göttgens EL, Krieg AJ, Hammond EM. Epigenetic therapy for solid tumors: highlighting the impact of tumor hypoxia. Genes (Basel). 2015;6:935–56.

Article  CAS  PubMed  Google Scholar 

Wilson C, Krieg AJ. KDM4B: a nail for every hammer? Genes (Basel). 2019;10:134.

Article  CAS  PubMed  Google Scholar 

Ueda T, Kanai A, Komuro A, Amano H, Ota K, Honda M, et al. KDM4B promotes acute myeloid leukemia associated with AML1-ETO by regulating chromatin accessibility. FASEB Bioadv. 2021;3:1020–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horiuchi K, Umetani M, Minami T, Okayama H, Takada S, Yamamoto M, et al. Wilms’ tumor 1-associating protein regulates G2/M transition through stabilization of cyclin A2 mRNA. Proc Natl Acad Sci USA. 2006;103:17278–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horiuchi K, Umetani M, Minami T, Okayama H, Takada S, Yamamoto M, et al. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia. 2014;28:1171–4.

Article  Google Scholar 

Jin DI, Lee SW, Han ME, Kim HJ, Seo SA, Hur GY, et al. Expression and roles of Wilms’ tumor 1-associating protein in glioblastoma. Cancer Sci. 2012;103:2102–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie W, Liu N, Wang X, Wei L, Xie W, Sheng X. Wilms’ tumor 1-associated protein contributes to chemo-resistance to cisplatin through the Wnt/β-catenin pathway in endometrial cancer. Front Oncol. 2021;11:598344.

Article  PubMed  PubMed Central